Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,047 people, all of whom received the HIV medication maraviroc. Of those, 1,032 were included in the safety analysis, and 916 completed the study. The trial was designed to track a range of safety-related measurements in people taking maraviroc, including how often participants experienced serious side effects, abnormal blood test results, AIDS-defining illnesses (serious conditions that can occur when the immune system is severely weakened), and other HIV-related infections or cancers. The reported data shows that 13.2% of participants experienced a Grade 3 ("severe") adverse event — meaning a side effect serious enough to interrupt daily life — and 2.4% experienced a Grade 4 ("very severe") adverse event, defined as intolerable, irreversible, or life-threatening. When looking only at side effects considered possibly related to the study drug, those figures were 6.3% and 1.6% respectively. For abnormal blood test results, the reported data shows a range of figures across different tests: Grade 3 (severe) abnormalities ranged from roughly 0.2% to 4.7% depending on the specific test, while Grade 4 (very severe) abnormalities ranged from 0% to about 1.5%. The percentage of participants who developed AIDS-defining illnesses was low across the categories measured, with most figures reported at 0.1% to 0.6%. The reported data shows that no measurements were submitted for the two outcome measures examining AIDS-related infections and cancers broken down by starting viral load or CD4 cell count (a measure of immune system strength). These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 HIV and AIDS Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your current HIV treatment is not working well enough, and a recent blood test shows your HIV virus levels are at 1,000 copies per milliliter or higher
- Your HIV virus is a specific type called "R5" (also known as CCR5-tropic), confirmed by a specific laboratory test called the Trofile assay
- You are at least 16 years old, or meet the minimum adult age required in your country
Who may not be able to join:
- You have previously tried and failed a type of HIV medication called a "CCR5 antagonist" (a drug that blocks a protein the virus uses to enter cells), or you are currently in another trial using this type of drug, or you previously stopped taking a drug called Maraviroc early while in a clinical trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
11 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With Grade 3 and Grade 4 Adverse Events (AE); Percentage of Participants With Grade 3 Laboratory Abnormalities Without Regards to Baseline Abnormalities; Percentage of Participants With Grade 4 Laboratory Abnormalities Without Regards to Baseline Abnormalities; Percentage of Participants With Acquired Immunodeficiency Syndrome (AIDS)-Defining Illnesses; Percentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Baseline Viral Load; Percentage of Participants With Possible Acquired Immunodeficiency Syndrom...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.